Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients

Oncology

Volumn 69, Issue 1, 2005, Pages 27-34

  Santini, Daniele ^a   Vincenzi, Bruno ^a   La Cesa, Annalisa ^a   Caricato, Marco ^a   Schiavon, Gaia ^a   Spalletta, Bruno ^b   De Seri, Marisa ^b   Coppola, Roberto ^a   Rocci, Laura ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Capecitabine; Chronomodulation; Oxaliplatin; Pretreated metastatic colorectal cancer patients

Indexed keywords

CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PROTON PUMP INHIBITOR;

ACUTE TOXICITY; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHRONOTHERAPY; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 23944505197     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087285     Document Type: Article

References (56)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics 2001. CA Cancer J Clin 2001;5:15-36.
2. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics 2004. CA Cancer J Clin 2004;54:8-29.
3. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomised trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol 1992;10:904-911.
4. Kohne-Wompner CH, Schmoll HJ, Harstrick A, Rustum YM: Chemotherapeutic strategies in metastatic colorectal cancer: An overview of current clinical trials. Semin Oncol 1992;19:105-125.
5. Pinedo HM, Peters GF: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988;6:1653-1664.
6. Scheithauer W, Rosen H, Kornek GV, et al: Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752-755.
7. Cunningham D, Pyrhonen S, James RD, et al: Randomized trial of irinotecan plus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
8. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047.
9. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
10. Misset JL, Bleiberg H, Sutherland W, et al: Oxaliplatin clinical activity: A review. Crit Rev Oncol Hematol 2000;35:75-93.
11. Raymond E, Faivre S, Woynarowski JM, Chaney SG: Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998;25:4-12.
12. De Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
13. Goldberg RM, Morton RF, Sargent DJ, et al: N9741:oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5-FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer: Updated efficacy and quality of life (QOL) data from an intergroup study. Proc ASCO 2003;22:252.
14. Diaz-Rubio E, Evans TR, Tabemero J, et al: Capecitabine (Xeloda) in combination with oxaliplatin: A phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002;13:558-565.
15. Reigner B, Blesch K, Weidekamm E: Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40:85-104.
16. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
17. Borner MM, Dietrich D, Stupp R, et al: Phase II study of capecitabine and oxaliplatin in first-and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002;20:1759-1766.
18. Zeuli M, Nardoni C, Pino MS, et al: Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 2003;14:1378-1382.
19. Scheithauer W, Kornek GV, Raderer M, et al: Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;2:1307-1312.
20. Adam R: Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003;14:13-16.
21. Garufi C, Brienza S, Pugliese P, et al: Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. Anticancer Drugs 2000;11:495-501.
22. Mormont MC, Waterhouse J, Bleuzen P, et al: Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 2000;6:3038-3045.
23. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
24. Levi F, Zidani R, Brienza S, et al: A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer 1999;85:2532-2540.
25. Rosati G, Rossi A, Tucci A, et al: Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. Ann Oncol 2001;12:669-674.
26. Santini D, Massacesi C, D'Angelillo RM, et al: Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: A multicenter non-randomized phase II study. Med Oncol 2004;21:59-66.
27. Kemeny N, Tong W, Gonen M, et al: Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol 2002;13:1490-1496.
28. MacDonald J, Haller D, Mayer R: Grading of toxicity; in MacDonald J, Haller D, Mayer R (eds): Manual of Oncologic Therapeutics. Philadelphia, Lippincott, 1995, pp 519-523.
29. Thall PF, Simon R, Ellenberg SS: A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 1989;45:537-547.
30. Ducreux M, Ychou M, Seitz JF, et al: Irinotecan combined with bolus fluorouracil, continous infusion fluorouracil, and high dose leucovorin every two weeks (LV 5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999;17:2901-2908.
31. Wasserman E, Cuvier C, Lokiec F, et al: Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999;17:1751-1759.
32. Durrani ASK, Benhammouda A, Gil-Delgado MA, et al: Combination of irinotecan with leucovorin and 5-FU in advanced colorectal carcinoma. Proc ASCO 1999;18:282.
33. André T, Louvet C, Maindrault-Goebel F, et al: CPT-11 (irinotecan) addition to bimonthly, high dose leucovorin and bolus continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur J Cancer 1999;35:1343-1347.
34. André T, Louvet C, Raymond E, et al: Bimonthly high dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX 3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998;9:1251-1253.
35. André T, Bensmaine MA, Louvet C, et al: Multicentre phase II study of bimonthly high dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-3568.
36. Rougier P, Lepille D, Bennouna J, et al: Anti-tumour activity of three second line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: A randomized multicentre phase II study. Ann Oncol 2002;13:1558-1567.
37. Borner MM, Dietrich D, Stupp R, et al: Phase II study of capecitabine and oxaliplatin in first-and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002;1;20:1759-1766.
38. Sumpter K, Harper-Wynne C, Cunningham D, et al: Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: A single institution's experience. Clin Oncol (R Coll Radiol) 2003;15:221-226.
39. Pfeiffer P, Hahn P, Jensen HA: Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. Acta Oncol 2003;42:832-836.
40. Rothenberg ML, Eckardt JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-1135.
41. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, et al: Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999;35:54-59.
42. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
43. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
44. Shields AF, Zalupski MM, Marshall JL, Meropol NJ: Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: A phase II trial. Cancer 2004;100:531-537.
45. Cassidy J, Tabernero J, Twelves C, et al: Xelox (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-2091.
46. Jordan K, Kellner O, Kegel T, et al: Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Clin Colorectal Cancer 2004;4:4650.
47. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
48. Hochster H, Chachoua A, Speyer J, et al: Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol 2003;21:2703-2707.
49. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-237.
50. Sorbye H, Glimelius B, Berglund A, et al: Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004;22:31-38.
51. Simpson D, Dunn C, Curran M, Goa KL: Oxaliplatin: A review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs 2003;63:2127-2156.
52. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
53. Cassidy J, Twelves C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-575.
54. Hoff PM, Pazdur R, Lassere Y, et al: Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 2004;22:2078-2083.
55. Scheithauer W, McKendrick J, Begbie S, et al: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 2003;14:1735-1743.
56. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001;19:4097-4106.